Gilead's three-drug HIV regimen wins European panel approval
(Reuters) - Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.
from Reuters: Health News https://reut.rs/2FkcSKb
http://bit.ly/2zwRqiM
April 27, 2018
|
Labels:
health,
Reuters: Health News
|
This entry was posted on April 27, 2018
and is filed under
health
,
Reuters: Health News
.
You can follow any responses to this entry through
the RSS 2.0 feed.
or trackback from your own site.